REG - GSK PLC - ViiV LAI vs oral SOC data in adherence-challenged

GSKAnnouncement

06/03/2024 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240306:nRSF8788Fa&default-theme=true

RNS Number : 8788F  GSK PLC  06 March 2024

Issued: 6 March 2024, London UK

 

ViiV Healthcare announces interim data at CROI indicating superior efficacy of
long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine)
compared to daily oral therapy in individuals living with HIV who have
adherence challenges

 

 

 

London, 06 March 2024 - ViiV Healthcare, the global specialist HIV company
majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders,
today announced data from a planned interim analysis of the LATITUDE phase III
trial, indicating that their long-acting injectable antiretroviral treatment
(ART) for HIV, Cabenuva (cabotegravir + rilpivirine), demonstrated superior
efficacy in maintaining viral load suppression compared to daily oral therapy
in individuals with a history of ART adherence challenges.

 

The data were presented by the Advancing Clinical Therapeutics Globally for
HIV/AIDS and Other Infections (ACTG) network at the Conference on Retroviruses
and Opportunistic Infections (CROI), in Denver, Colorado.

 

Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare
said, "It's estimated that one-third of people living with HIV in the United
States struggle with maintaining viral suppression. The findings of the
LATITUDE study show that long-acting injectable cabotegravir + rilpivirine
could be important for some people in this group, giving them another option
to help keep their virus under control and improve their health. Further,
since we know that individuals whose virus is undetectable don't transmit to
sexual partners, this could be an important contribution to ending the HIV
epidemic."

 

LATITUDE is a phase III, randomised, open-label study. Participants received
comprehensive and incentivised adherence support while taking
guideline-recommended, three-drug regimen oral ART, including dolutegravir and
bictegravir-based regimens, to achieve viral suppression. Those who achieved
viral suppression were eligible to randomise to staying on oral standard of
care (SOC) regimens or switch to long-acting injectable cabotegravir +
rilpivirine (LA-ART) dosed monthly.

 

During the randomised phase of the study, 146 participants received monthly
LA-ART and 148 continued on SOC. The primary endpoint was a comparison of
regimen failure, defined as a combination of virologic failures (VF) and
regimen discontinuations, between arms. 24.1% of participants on LA-ART
experienced regimen failure compared to 38.5% on SOC {difference -14.4 (98.75%
CI -29.8%, -0.8%)}.

 

Although the primary endpoint did not meet the strict predefined stopping
criterion for the interim analysis, key secondary endpoints of virologic
failure (7.2% LA-ART vs. 25.4% SOC {difference -18.2% (98.75% CI-31.1%,
-5.4%}) and treatment-related failure (9.6% LA-ART vs 26.2% SOC {difference
-16.6% (98.75% CI -29.9%, -3.3%)} favoured the LA-ART regimen. The study's
Data Safety Monitoring Board (DSMB) considered the totality of all the study
endpoints together and concluded that the evidence indicated superior efficacy
of long-acting ART over daily oral standard of care. The DSMB recommended that
all eligible participants should be offered long-acting injectable
cabotegravir + rilpivirine.

 

The rate of adverse events (AEs) was similar in both arms. Three participants
in the LA-ART arm had serious injection site reactions (ISR) and one
participant discontinued due to an ISR. Two confirmed virologic failures in
each arm had new resistance associated mutations (RAMS), including at least
two new integrase inhibitor RAMs in both LA-ART participants.

 

The LATITUDE (Long-Acting Therapy to Improve Treatment Success in Daily Life)
study is ongoing across 31 sites in the U.S. including Puerto Rico,
implemented through ACTG. The median age of study participants was 40 years
old; 40 percent of participants were male, 64 percent were Black/African
American, 17 percent were Hispanic, 5 percent were transgender, and 14 percent
currently or previously used injection drugs. The study is sponsored and
funded by the National Institute of Allergy and Infectious Diseases (NIAID),
part of the National Institutes of Health, and is being conducted by ACTG,
with additional support from the National Institute of Mental Health, the
National Institute on Drug Abuse, ViiV Healthcare and the Janssen
Pharmaceutical Companies of Johnson & Johnson.

 

About Cabenuva (cabotegravir + rilpivirine)

Cabenuva is indicated as a complete regimen for the treatment of HIV-1
infection in adults to replace the current antiretroviral regimen in those who
are virologically suppressed (HIV-1 RNA <50 c/ml) on a stable
antiretroviral regimen with no history of treatment failure and with no known
or suspected resistance to either cabotegravir or rilpivirine.

 

The complete regimen combines the integrase strand transfer inhibitor (INSTI)
cabotegravir, developed by ViiV Healthcare, with rilpivirine, a non-nucleoside
reverse transcriptase inhibitor (NNRTI) developed by Janssen Sciences Ireland
Unlimited Company. Rilpivirine tablets are approved in the US as a 25mg tablet
taken once a day to treat HIV-1 in combination with other antiretroviral
agents in antiretroviral treatment-naïve patients 12 years of age and older
and weighing at least 35kg with a viral load ≤100,000 HIV RNA c/ml.

 

INSTIs inhibit HIV replication by preventing the viral DNA from integrating
into the genetic material of human immune cells (T-cells). This step is
essential in the HIV replication cycle and is also responsible for
establishing chronic disease. Rilpivirine is an NNRTI that works by
interfering with an enzyme called reverse transcriptase, which stops the virus
from multiplying.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

Please consult the full Prescribing Information (https://cabenuvahcp.com/)
. 1 

 

About ACTG

ACTG is the world's largest and longest running clinical trials network
focused on HIV and other infectious diseases and the people living with them.
It is funded by NIAID and collaborating NIH Institutes. Founded in 1987, ACTG
conducts research to improve the management of HIV and its comorbidities;
develop a cure for HIV; and innovate treatments for tuberculosis, hepatitis B,
and emerging infectious diseases. It comprises thousands of dedicated
researchers, staff, and community members who are pursuing research into novel
treatments and cures for infectious diseases at hundreds of locations across
four continents, with the ultimate goal of advancing science that meaningfully
impacts the lives of the people we serve.

 

 

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November
2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances
in treatment and care for people living with HIV and for people who are at
risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012. The
company's aims are to take a deeper and broader interest in HIV and AIDS than
any company has done before and take a new approach to deliver effective and
innovative medicines for HIV treatment and prevention, as well as support
communities affected by HIV.

 

For more information on the company, its management, portfolio, pipeline, and
commitment, please visit viivhealthcare.com.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 Media enquiries:     Tim Foley          +44 (0) 20 8047 5502  (London)
                      Sarah Clements     +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)
                      Alison Hunt        +1 540 742 3391       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  44 (0) 7796 707505    (London)
                      Jeff McLaughlin    + 1 215 751 7002      (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in the company's Annual Report on Form 20-F for 2023.

 
 Registered in England & Wales:
 GSK plc
ViiV Healthcare Limited
 No. 3888792                             No.
06876960

 

Registered Office:
 GSK plc                                    ViiV Healthcare
Limited
 980 Great West Road               GSK Medicines Research Centre
 Brentford, Middlesex                 Gunnels Wood Road, Stevenage
 
 United Kingdom                        United Kingdom
 TW8 9GS                                  SG1 2NY

 

 1  https://cabenuvahcp.com/ (https://cabenuvahcp.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDKZGGFKVMGDZM